Projects funded by the NCN
Combined administration of muscarinic receptor antagonists and group II/III metabotropic glutamate (mGlu) receptor ligands as a novel efficacious method to treat depression - the preclinical studies
2020/37/B/NZ7/03499
Keywords:
Depression scopolamine muscarinic receptors M1 receptors M2 receptors M3 receptors M4 receptors M5 receptors metabotropic receptors for glutamate mGlu2 receptors mGlu3 receptors mGlu7 receptors antidepressant effects
Descriptors:
- NZ7_14: Pharmacy, pharmacotherapy, pharmacology
- NZ5_7: Human disease treatment
Panel:
NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution :
Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk
woj. małopolskie
Principal investigator (from the host institution):
Number of co-investigators in the project: 6
Call: OPUS 19 - announced on 2020-03-16
Amount awarded: 2 980 248 PLN
Project start date (Y-m-d): 2021-01-14
Project end date (Y-m-d): 2025-01-13
Project duration:: 48 months (the same as in the proposal)
Project status: Pending project
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.